SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 ...

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer Transformative moment ...

Evotec SE: Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation

Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancerTransformative moment in ...
Frontiers

Transformer-Enabled Multi-Omics Interpretation: LLM Pipelines for Cross-Dataset Annotation and Uncertainty-Aware Integration

You will be redirected to our submission process. Multi-omics studies now span genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, and spatial and single-cell modalities, ...